90
Participants
Start Date
June 30, 2003
Primary Completion Date
August 31, 2012
Study Completion Date
August 31, 2012
zoledronic acid
Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
dexamethasone
As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
thalidomide
As outlined in Thalidomide and Dexamethasone Treatment arm
vincristine
As outlined in VAD Treatment Arm
adriamycin
As outlined in VAD Treatment arm
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Morton Plant Hospital, Clearwater
Watson Clinic, Lakeland
Fawcett Memorial Hospital, Port Charlotte
San Juan VA Hospital, San Juan
Collaborators (1)
Novartis
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER